📰 Seth Lederman News
Page 3 - Seth Lederman News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Seth Lederman. Real-time updates on events, politics, business and more.
November 28, 2023
28.11.2023 - CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix Management will present and ... Seite 1
November 20, 2023
Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to shed light on the latest developments in their research efforts. The company has successfully concluded the...
November 17, 2023
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Dr. Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine,...
November 17, 2023
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Dr. Seth Lederman recently joined Steve Darling from Proactive to shed light on the latest developments in their...
November 16, 2023
Are you in a position where you can assume the risk?
November 16, 2023
What do sports medicine and business franchises have in common? Seth Lederman. He’s been in both businesses and helping people find their perfect franchise (or turning their successful business into a franchise) is what really gets him out of bed in the morning. “I was a successful spine and sports medicine physician. As you know, […]
October 31, 2023
The study did not achieve statistical significance on the primary endpoint Tonix is discontinuing development of TNX-601 ER based on the efficacy results...
October 30, 2023
30.10.2023 - Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is currently in Phase 1 Clinical Development Tonix is Developing TNX-1500 for Prevention of Kidney Allograft Rejection as the First ... Seite 1
October 26, 2023
Tonix Pharmaceuticals (NASDAQ:TNXP) said it expects to receive the topline results from its 88-patient Phase 2 PREVENTION study of its investigational drug...